Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

John Violet(Peter MacCallum Cancer Centre), Shahneen Sandhu(Peter MacCallum Cancer Centre), Amir Iravani(Peter MacCallum Cancer Centre), Justin Ferdinandus(Peter MacCallum Cancer Centre), Sue-Ping Thang(Peter MacCallum Cancer Centre), Grace Kong(Peter MacCallum Cancer Centre), Aravind Ravi Kumar(Peter MacCallum Cancer Centre), Tim Akhurst(Peter MacCallum Cancer Centre), David A. Pattison(Peter MacCallum Cancer Centre), Alexis Beaulieu(Peter MacCallum Cancer Centre), Jennifer Mooi(Peter MacCallum Cancer Centre), Ben Tran(Peter MacCallum Cancer Centre), Christina Guo(Peter MacCallum Cancer Centre), Victor Kalff(Peter MacCallum Cancer Centre), Declan G. Murphy(Peter MacCallum Cancer Centre), Price Jackson(Peter MacCallum Cancer Centre), Peter Eu(Peter MacCallum Cancer Centre), Mark Scalzo(Peter MacCallum Cancer Centre), Scott Williams(Peter MacCallum Cancer Centre), Rodney J. Hicks(Peter MacCallum Cancer Centre), Michael S. Hofman(Peter MacCallum Cancer Centre)
Journal of Nuclear Medicine
November 15, 2019
10.2967/jnumed.119.236414
Cited by 279Open Access
Full Text

Abstract

Lu-PSMA demonstrated higher response rates than other systemic therapies.

Related Papers

No related papers found

Powered by citation graph analysis